WALTHAM, Mass., Sept. 30, 2022 Apellis Pharmaceuticals, Inc. , a global biopharmaceutical company and leader in complement, today announced that four oral presentations of data from the Phase 3. | September 30, 2022
Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) have been assigned an average recommendation of “Buy” from the fourteen research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nine have assigned a buy recommendation and one […]
Apellis Pharmaceuticals, Inc. (NASDAQ:NASDAQ:APLS) Q1 2022 Earnings Conference Call May 04, 2022, 16:30 ET Company Participants Meredith Kaya - SVP, IR & Strategic Finance Adam Townsend.